全文获取类型
收费全文 | 158篇 |
免费 | 18篇 |
国内免费 | 18篇 |
专业分类
儿科学 | 5篇 |
妇产科学 | 4篇 |
基础医学 | 28篇 |
口腔科学 | 1篇 |
临床医学 | 25篇 |
内科学 | 72篇 |
皮肤病学 | 1篇 |
神经病学 | 2篇 |
特种医学 | 3篇 |
外科学 | 7篇 |
综合类 | 6篇 |
预防医学 | 12篇 |
眼科学 | 7篇 |
药学 | 14篇 |
肿瘤学 | 7篇 |
出版年
2021年 | 4篇 |
2020年 | 2篇 |
2017年 | 2篇 |
2016年 | 2篇 |
2015年 | 4篇 |
2013年 | 3篇 |
2011年 | 5篇 |
2010年 | 2篇 |
2009年 | 2篇 |
2008年 | 3篇 |
2007年 | 13篇 |
2006年 | 2篇 |
2005年 | 6篇 |
2004年 | 2篇 |
2002年 | 2篇 |
2001年 | 6篇 |
1999年 | 9篇 |
1998年 | 6篇 |
1997年 | 7篇 |
1996年 | 12篇 |
1995年 | 4篇 |
1994年 | 5篇 |
1993年 | 9篇 |
1992年 | 2篇 |
1991年 | 4篇 |
1990年 | 3篇 |
1989年 | 4篇 |
1988年 | 6篇 |
1987年 | 3篇 |
1986年 | 2篇 |
1985年 | 4篇 |
1984年 | 2篇 |
1983年 | 5篇 |
1982年 | 4篇 |
1981年 | 3篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1975年 | 5篇 |
1972年 | 2篇 |
1970年 | 2篇 |
1969年 | 3篇 |
1967年 | 3篇 |
1966年 | 1篇 |
1965年 | 3篇 |
1964年 | 1篇 |
1963年 | 1篇 |
1960年 | 1篇 |
1958年 | 1篇 |
1954年 | 1篇 |
排序方式: 共有194条查询结果,搜索用时 15 毫秒
1.
Facilitated uptake of zinc into human erythrocytes. Relevance to the treatment of sickle-cell anaemia 总被引:1,自引:0,他引:1
R C Hider L Ejim P D Taylor R Gale E Huehns J B Porter 《Biochemical pharmacology》1990,39(6):1005-1012
The ability of a number of heterocyclic metal chelators to deliver zinc into red cells, to release the liganded zinc to haemoglobin and thereby cause a left shift in the oxygen dissociation curve of intact red cells has been investigated. Incubation of neutrally charged zinc-pyrone and zinc-pyridin-2-one complexes with red cells led to the rapid accumulation of zinc within cells, whereas unliganded zinc in the form of zinc acetate, zinc chloride or zinc sulphate accumulated only slowly. The rate at which zinc was delivered to red cells by pyrone and pyridin-2-one ligands increased with increasing lipid solubility of the ligands. The uptake of zinc into both normal adult and sickle red cells was associated with a dose-dependent increase in the oxygen affinity of haemoglobin. The degree of left shift in the oxygen dissociation curve following the incubation of red cells with zinc-pyrone and -pyridin-2-one complexes suggests that these complexes may find application as agents to increase the oxygen affinity of haemoglobin in sickle cell disease and thereby decrease the probability of intravascular sickling at low tissue oxygen tensions. Ethylmaltol appears to be a particularly useful agent due to its known low toxicity. 相似文献
2.
黑柴胡中新三萜皂甙的结构鉴定 总被引:3,自引:0,他引:3
从黑柴胡(Bupleurum smithii Wolff)根中分离出10个化合物,均为首次由该植物中获得。其中二个新三萜皂甙,即柴胡皂甙k和l(saikosaponin k and l),其结构经紫外、红外、核磁共振氢谱,碳谱和质谱等波谱测定和解析,分别确定为3β,16β,23,28-四羟基齐墩果烷-11,13(18)-二烯-3-O-β-D-吡喃木糖基-(1→2)-β-D-吡喃葡萄糖基-(1→3)-β-D-吡喃呋糖甙和3β,16α,23,28,30-五羟基齐墩果烷-11,13(18)-二烯-3-O-β-D-吡喃葡萄糖基-(1→3)-β-D-吡喃呋糖甙。 相似文献
3.
Nikol S Maier A Krausz E Höfling B Huehns TY 《BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy》1998,9(5):375-388
No systemic pharmacological treatment has been convincingly shown to reduce the incidence of restenosis after angioplasty in patients. The lack of success of many pharmaceutical agents in reducing restenosis rates post-angioplasty and following stent implantation, as documented in dozens of clinical trials, has encouraged the development of new biotechnological approaches to the treatment of restenosis. Gene therapy and other agents, including antibodies, fusion toxins and ribozymes, have the potential to prevent some of the sequelae after arterial injury, particularly cell proliferation. Mechanical methods of preventing restenosis, for example sophisticated local drug delivery strategies and biodegradable stents using new materials, in combination with novel therapeutic agents or radiation, may also be of use. 相似文献
4.
Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin 总被引:23,自引:3,他引:23
Interleukin-11 (IL-11) is a novel multifunctional hematopoietic cytokine capable of stimulating cells of the myeloid, lymphoid, erythroid, and megakaryocytic lineages in vitro. We have tested the pleiotropic properties of this cytokine on the hematopoietic recovery of mice after a combined regimen of sublethal irradiation and carboplatin administration. This regimen results in severe myelosuppression, characterized by a prolonged period of thrombocytopenia and severe anemia. Administration of recombinant human IL-11 (rhIL-11; 250 micrograms/kg/d) had multilineage effects on bone marrow and spleen hematopoietic activity, increasing the number of megakaryocyte, erythroid, granulocyte, and macrophage progenitors compared with the vehicle-treated controls. This was reflected in the peripheral circulation by a reduction of both the platelet and hematocrit nadirs and a significantly reduced period of thrombocytopenia and anemia in the rhIL-11-treated mice. The results from this study support the broad spectrum of biologic activities that have been attributed to rhIL-11 in vitro and suggest that this cytokine may be an effective agent in the treatment of myelosuppression associated with cancer chemotherapy and bone marrow transplantation. 相似文献
5.
Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4- one iron chelators in overloaded and nonoverloaded mice 总被引:3,自引:1,他引:3
Five orally effective iron chelators of the 3-hydroxypyridin-4-one series have been administered intraperitoneally to iron-overloaded and nonoverloaded male mice at a dose of 200 mg/kg/24 h for a total of 60 days to investigate the effect on iron loading and toxicity. There was a significant reduction in hepatic iron at the end of the study in the iron-overloaded mice with all compounds studied using chemical iron quantitation (P less than .001) and with Perls' stain (P less than .01). Liver iron removal with the hydroxypyridinones ranged from 37% with CP20 to 63% with CP51, compared with 46% removal for desferrioxamine (DFO). There was no significant reduction in splenic or cardiac iron with any chelator. There were no deaths in iron-overloaded animals receiving any of the hydroxypyridin-4-ones, but significantly more deaths in the nonoverloaded groups as a whole (P less than .03). No weight loss was observed with any chelator. Significant reductions in hemoglobin and white cell count were observed with CP20(L1). No histologic abnormalities of kidney, spleen, bone marrow, or stifle joints were observed. Intracytoplasmic inclusion bodies were observed in the centrilobular hepatocytes of animals administered each of the hydroxypyridin-4-ones, while the DFO-treated and control groups showed no such changes. 相似文献
6.
No systemic pharmacological treatment has been shown to convincingly reduce the incidence of restenosis after angioplasty or increase the formation of collaterals in ischemic tissue in patients. The lack of success of many pharmaceutical agents in reducing restenosis rates or in inducing angiogenesis post-angioplasty and following stent implantation has encouraged the development of new technological treatment approaches. Gene therapy is a novel strategy with the potential to prevent some of the sequelae after arterial injury, particularly cell proliferation, and to induce growth of new vessels or remodeling of pre-existing vessel branches, which may help patients with critical ischemia. Gene therapy strategies have the advantage of minimizing systemic side effects and may have a long-term effect as the encoded protein is released. Most clinical trials investigating gene therapy for vascular disease have been uncontrolled phase I and IIa trials. Gene therapy into vessels with the genes for growth factors has been demonstrated to be feasible and efficient. Local drug delivery devices have been used in combination with gene therapy in several trials to maximize safety and efficiency. Data from experimental animal work indicates that gene therapy may modify intimal hyperplasia after arterial injury, but there are few clinical trials on restenosis in patients. Preliminary clinical results show only limited success in altering restenosis rates. In vitro and experimental in vivo investigations into gene therapy for angiogenesis demonstrate increased formation of collaterals and functional improvement of limb ischemia. There is some evidence of increased collateral formation and clinical improvement in patients with critical limb ischemia. Results of placebo-controlled and double-blind trials of gene therapy for vascular disease are awaited. 相似文献
7.
8.
9.
Idiopathic Heinz Body Anaemia: Hb-Bristol (β67 (E11) Val→Asp) 总被引:4,自引:0,他引:4
S ummary . It is shown that the haemolytic anaemia in the original patient with 'idiopathic Heinz body anaemia' is due to the presence of 36% unstable haemoglobin: Hb-Bristol (β67 (E11) Val→Asp). This haemoglobin has a low oxygen affinity which accounts for the normal development of this patient in spite of the presence of permanent severe anaemia. The relative rates of synthesis of βBristol - to βA -chains were identical, indicating that the reduced amount of Hb-Bristol found in the haemolysate is due to precipitation of the abnormal protein. The inability to separate this haemoglobin by electrophoresis is due to interaction of the abnormal aspartic acid with the adjacent histidine at β63 (E7). 相似文献
10.